Katherine B. Winfree

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Ralph Zinner, Coleman K. Obasaju, David R. Spigel et al. · Journal of Thoracic Oncology · 2014 · 171 citations · Full text

Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Cesare Gridelli, Filippo de Marinis, Jean-Louis Pujol et al. · Journal of Thoracic Oncology · 2012 · 55 citations · Full text

Oncology, Cancer Management, Resource Use +5

Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer

Lisa M. Hess, Anthony Louder, Katherine B. Winfree et al. · Journal of Managed Care & Specialty Pharmacy · 2017 · 41 citations · Full text

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin

Martin Reck, Nick Thatcher, Egbert F. Smit et al. · Lung Cancer · 2012 · 35 citations

Prognostic Factors, Medicine, Cancer Management +7

Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy

Suzanne McMullen, Lisa M. Hess, Edward S. Kim et al. · Patient · 2018 · 35 citations · Full text